The MelbourneTheranostic Innovation Centre (MTIC) was honored to partner with Alpha9 Oncology be the site that performed the first-in-human dosing and imaging of 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor(MC1R) for the imaging of locally advanced or metastatic melanoma. MC1R expression is known to be elevated in malignant melanoma and other types of skin cancers.
As a patient and research-focused theranostic centre, MTIC's mission is to help advance nuclear medicine in the clinical setting so that novel diagnostic and therapeutic agents can eventually reach patients facing cancers with unmet needs.
We were delighted to apply the advanced molecular imaging possible with our Siemens Biograph Vision Quadra PET/CT, and MTIC wishes to thank our nurses & nuclear medicine technologists who made everything go smoothly and took good care of the patient.
The entire MTIC team looks forward to continue working with Alpha-9 Oncology as the study progresses.
